医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Solasia Announces Patient Registration Reached Target Number of Cases for Darinaparsin Phase 2 Pivotal Study for T-Cell Lymphoma

2019年09月17日 PM07:33
このエントリーをはてなブックマークに追加


 

TOKYO

Solasia Pharma K.K. (TSE:4597, Headquarters: Tokyo, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today announced that patient registration reached the target number of cases for the darinaparsin Phase 2 study.

The Phase 2 study is being conducted as a multinational, multicentre, single-arm, open-label, non-randomized study to evaluate the efficacy and safety of darinaparsin monotherapy in relapsed or refractory patients with peripheral T-cell lymphoma (hereinafter “PTCL”) in Japan, South Korea, Taiwan and Hong Kong. Patients would receive maximum 6 cycles of darinaparsin, and the efficacy would be measured with tumor response as primary outcome measure.

This study is a pivotal (final) study for PTCL based on prior consultation with the authority. At present, Solasia expects to announce the study results in 2020.

Solasia holds an exclusive worldwide license to develop and commercialize darinaparsin. For Japan market, Solasia has already entered into an exclusive license agreement with Meiji Seika Pharma Co., Ltd., for the commercialization of darinaparsin, and for Latin America, with HB Human BioScience SAS. Going forward, Solasia will actively seek licensing partners outside of Asia.

Through the active development of darinaparsin, Solasia will continue to strive for providing new treatment option for PTCL patients. Furthermore, Solasia will continue to pursuit the possibility for developing other indications in cancer field following PTCL.

About darinaparsin
Darinaparsin is a novel mitochondrial-targeted agent (organoarsenic) being developed for the treatment of various hematologic and solid cancers. In a US Phase 2 study, darinaparsin demonstrated evidence of clinical activity in lymphoma, in particular PTCL. Furthermore, the Phase 1 study done in US, and the Pan-Asian Phase 1 study both demonstrated positive efficacy and safety. Darinaparsin has been granted orphan drug designation in US and EU. For more information, please see at https://www.solasia.co.jp/en/pipeline/sp-02.html

About Solasia
Solasia is a specialty pharmaceutical company based in Asia, with a mission of “Better Medicine for a Brighter Tomorrow”. In order to address the unmet medical needs within the oncology area, we develop innovative medicines to contribute to the patient’s healthy living and to provide treatment options for the healthcare providers. For more information, please visit https://www.solasia.co.jp/en/

View source version on businesswire.com: https://www.businesswire.com/news/home/20190917005574/en/

CONTACT

Solasia Pharma K.K.

Rie Toyoda, Public Relations and Investor Relations,

Tel. +81 3 5843 8049

info@solasia.co.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 患者安全运动基金会、美国麻醉师协会、Leapfrog集团和国际医疗保健品质协会共同举办#UniteForSafeCare世界患者安全日活动
  • 武田宣布2020财年第一季度业绩;确认管理层指引,并提高全年列报运营利润和列报净利润
  • Panasonic Corporation announces verification of inhibitory effect of hydroxyl radicals contained in water (nano-sized electrostatic atomized water particle) on novel coronavirus (SARS-CoV-2)
  •  JEOL: Release of the New Scanning Electron Microscope JSM-IT700HR
  • New Frontier Health Corporation Announces Executive Management Team Changes